Rocco (R.) Sciarrillo PhD

Immunopathology, Structure & function of antibodies LinkedIn

Training

Pharmaceutical Biotechnologies at "Alma Mater Studiorum" University of Bologna, Italy

Thesis

Molecular mechanisms of drug resistance - Novel therapies for cancer treatment

Research interests

  • antibody discovery
  • cancer pharmacology
  • chemotherapy resistance
  • molecular biology

Technology

  • cytotoxicity assays
  • RNA-sequencing
  • FACS
  • recombinant protein expression
  • (primary) cell culture
  • PCR
  • qPCR
  • in-vivo bioluminescent imaging

Resume

2019-present

Postdoctoral fellow at Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands

2014-2018

PhD program at the VUmc – Cancer Center, Amsterdam, The Netherlands

2012-2013

Research Associate – Antibody Discovery Group, Kymab LTD, Babraham Research Campus, Cambridge, United Kingdom

Feb. 2012-

Aug. 2012

Medical Advisor Jr. – Intelligence and New Product Planning (NPP), Corporate Marketing, Chiesi Farmaceutici SPA, Prama, Italy

2010-2011

Internship at Laboratory of Medical Oncology at the VUmc – Cancer Center, Amsterdam, The Netherlands

2005-2011

Master degree in Pharmaceutical Biotechnologies “Alma Mater Studiorum” University of Bologna, Italy

Other publications

  • Sciarrillo R et al., “Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma”, EBioMedicine, 2018 (doi: 10.1016/j.ebiom.2018.12.025)
  • Sciarrillo R et al., “Using RNA-sequencing to detect novel splice variants related to drug resistance in in vitro cancer models”,  J. Vis. Exp. (118), e54714, doi:10.3791/54714 (2016)
  • Wojtuszkiewicz A et al., “The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia”, Hematologica 2016 (doi: 10.3324/haematol.2016.142794)
  • Lee EC et al., “Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery”, Nature Biotechnology, 2014 (doi: 10.1038/nbt.2825)
  • Maftouh M et al., “Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia”, British Journal of Cancer, 2013 (doi: 10.1038/bjc.2013.681)